Recent Media Coverage

Comprehensive legislation to end this pandemic and prevent the next one is stalling in Congress. Here’s why it must pass

The Hill: Pandemics are a matter of national security — Congress should act like it

Ashley Arabasadi, Senior External Affairs Manager, Management Sciences for Health; Carolyn Reynolds, Co-founder, Pandemic Action Network, November 26, 2021

The COVID-19 pandemic is far from over, yet Congress seems to have already put it in the rearview mirror. It is true that lawmakers took important steps over the past year to address the economic and health impacts of the virus here in the U.S. and abroad. But as cases and deaths continue to mount, it’s time to do much more. Right now, there’s a comprehensive piece of legislation wending its way through Congress that we believe is America’s best shot at ending this pandemic and preventing future ones.

Sadly, the bill—which had been an all-too-rare bright spot of bipartisan agreement on the need to tackle a grave threat to our national and global security—is now hanging by a thread, because political infighting has eclipsed saving lives.

The International Pandemic Preparedness and COVID-19 Response Act (S.2297) would do several necessary things. First, it would help close the dramatic inequity in access to COVID-19 vaccines by supporting the distribution of more U.S. vaccines that we don’t need to partner countries that do.



At this week’s White House pandemic summit and beyond, all eyes are on the United States

Think Global Health: The World Needs U.S. Funding to Prevent and Prepare for the Next Pandemic

Ashley Arabasadi, Senior External Affairs Manager, Management Sciences for Health; Neil M. Vora, Fellow, Conservation International; Pasha Majdi, Senior Director for U.S. Policy and Government Affairs, Conservation International, September 20, 2021

For too long, we have ignored how our actions—from deforestation to wildlife trade—drive infectious disease outbreaks. We also have not invested in controlling them. Global health security initiatives have been underfunded, even in the midst of epidemics, such as Zika virus in the Americas in 2016. COVID-19 is an opportunity to break free of this inertia, but the movement needs a leader—the United States must fund and coordinate pandemic prevention and preparedness. 


Leveraging Partnerships and Technology to Optimize Medical Supply Chains

Next Billion: Improving COVID-19 Vaccine Distribution Around the World

Marian W. Wentworth and Wade Warren, June 28, 2021

The prospect of delivering the COVID-19 vaccine in low- and middle-income countries (LMIC) is more daunting than childhood vaccine delivery, mostly because the target population for vaccination is novel and the systems are not yet developed to efficiently accomplish adult immunization. In addition to ensuring the developed vaccines are appropriate for specific LMIC contexts, the distribution system—the supply chain—must be established, local medical policies created, health systems improved to include adult immunization, and community trust and support cultivated. Ad hoc programs are not enough, because countries will need to reach the same beneficiaries several times to facilitate vaccines that require two doses, as well as to administer future boosters and potentially conduct annual vaccination. But these challenges can be solved by technologies that facilitate supply chain monitoring, site-level information collection, beneficiary management, and data analytics. 


The importance of strong supply chains during a pandemic

Voice of America: How the Pandemic Disrupted Them and How Organizations Overcame

Gashaw Shiferaw, MSH Senior Technical Advisor, May 18, 2021

The COVID-19 pandemic has caused supply chain disruptions to many global production networks, from fish farming to pharmaceuticals. In an interview with Voice of America, MSH's Gashaw Shiferaw explains how the pandemic brought much-needed attention to the importance of having strong supply chains—work that organizations such as MSH have been focused on for years. Now is the time to leverage this focus and help advance countries' efforts to strengthen pharmaceutical and supply chain management systems. 


African nations’ reliance on medicine manufacturers in India and China leaves the continent vulnerable to medicine stock-outs

Bhekisisa: Four factors blocking medicines made in Africa

Francis Aboagye-Nyame, Program Director, Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program, April 26, 2021

The COVID-19 pandemic has highlighted long-standing weaknesses in the pharmaceutical systems of African countries: a shortage of manufacturing capacity, weak medicines regulatory systems, and poor accessibility of medical products. Along with gaps in African countries’ overall health systems, these problems help explain why about half of the continent’s people lack access to essential medicines and half a million children in Africa die of vaccine-preventable diseases each year. The African Union has called for the continent to do more of its own manufacturing to help ensure a sustainable supply of medicines. But to make that a reality, and ensure that the medicines produced in Africa are safe and effective, four things need to be in place. 


The black market for COVID-19 vaccines and proof of vaccination is growing rapidly as people tire of restrictions and are anxious to return to normalcy

Forbes: How Counterfeit COVID-19 Vaccines And Vaccination Cards Endanger Us All

Dr. Judy Stone, March 31, 2021

The black market for COVID vaccines and proof of vaccination is growing rapidly as people tire of restrictions and are anxious to return to normalcy. It is also driven by the inequitable distribution of vaccines, leaving many low- and middle-income (LMIC) countries behind.

Many of the dangers are obvious—a person may become more ill or die because of receiving an ineffective medicine for their illness. Less obvious is that counterfeit antibiotics can promote antibiotic resistance and fuel the spread of drug resistant organisms throughout communities.

Fake vaccines—substituting plain salt water for a vaccine, for example—might not cause immediate harm, but may fuel distrust about vaccines’ effectiveness. People will falsely assume that they are protected and engage in risky behaviors.

One of the problems with these scams is that they not only hurt individuals, but they hurt all of us. Until we get widespread vaccine uptake and herd immunity, we will not stop the spread of coronavirus, and mutant strains will proliferate.


The colossal undertaking of global vaccine rollout is facing another gargantuan challenge: monitoring their safety

Think Global Health: The Urgent Need to Better Monitor Vaccine Safety in the Real World

Dr. Javier Guzman, Technical Director, MTaPS, and Comfort Ogar, Principal Technical Advisor, Pharmacovigilance, March 24, 2021

The vaccines have proven to be safe and effective in clinical trials. Yet as with the rollout of any new medicine or treatment, it takes time to see the bigger picture. Clinical trials, including those for the COVID-19 vaccines, follow thousands of volunteers from a limited population for several months. Now billions of people all over the world will be inoculated with them, with a lifetime of consequences. Even as policymakers and experts communicate the benefits of the vaccines to win over the hesitant, we must monitor for unwelcome side effects. If these adverse events are not documented and publicly addressed, they can further undermine public confidence in the vaccines, and scientific medicine more generally. And right now, there are big blind spots in our global ability to do this.

Will the Covid-19 pandemic help make public health more valued, sustainable, and resilient?

STAT: Covid-19 could bring a new era of public health leadership. But will it?

Marian W. Wentworth, President and CEO, March 5, 2021

The bubonic plague—also known as the Black Death—killed as many as 200 million people in the mid-14th century, about one-third of the population of Europe. It was the deadliest epidemic in history, yet it gave birth to public health initiatives that survive today, including quarantines and checkpoints to stop the spread of disease.

In the wake of World War II, a wave of international collaboration created the World Health Organization. The HIV/AIDS epidemic spawned a new era of urgency and activism for international health efforts.

Great threats have historically been catalysts for change. Will the Covid-19 pandemic help make public health more valued, sustainable, and resilient? It's possible, but not without sustained commitment in five areas.


The pandemic may be interfering with our fight against drug-resistant bacteria. Luckily, the same tactics can beat back both scourges.

Knowable Magazine: Don’t let Covid boost another killer

Dr. Mohan Joshi, Senior Principal Technical Advisor and MTaPS’ Technical lead for Global Health Security Agenda (GHSA)/AMR activities, February 17, 2021

The COVID-19 pandemic may be interfering with our fight against drug-resistant bacteria. Luckily, the same tactics can beat back both scourges, writes Mohan P. Joshi, technical lead for issues related to antimicrobial resistance and global health security at Management Sciences for Health, in an opinion article for Knowable Magazine.  

Overburdened as they are, healthcare facilities have to recognize that efforts against both COVID-19 and antimicrobial resistance will work in tandem. Fighting one with surveillance, education and research will also help the other. Providers should integrate antimicrobial stewardship with all the measures they take to prevent and control contagious diseases such as COVID-19 and tuberculosis.

Coordinating our responses to both scourges—COVID-19 and antibiotic resistance—in every facility and in our global health security efforts is the most efficient and effective way to go. The payoff will be millions of lives saved from both.


The private sector is an often overlooked but essential partner in increasing access to medicines

Daily Monitor: Access to life-saving medicine calls for collaborations

Dr. Eric Lugada, Chief of Party for the MSH-led, USAID-funded Uganda Strengthening Supply Chain Systems Activity, January 16th 

"Whether we are working with people living with HIV or chronic diseases, there is no doubt that access to medicines is an integral part of a robust health system - a goal hard to achieve without strong multisectoral collaborations,” says MSH’s Dr. Eric Lugada. With PEPFAR, Global Fund, and USAID support, more Ugandans have access to medicines, including HIV treatment, thanks to efforts to strengthen the country's supply chain inventory and management systems. 

Working with the Ministry of Health, the USAID-funded Uganda Health Supply Chain Project and Uganda Strengthening Supply Chain Systems Activity, both implemented by MSH, developed a web-based system for health facilities to efficiently order HIV medicines. This system facilitates real-time data that allows the Ministry to design and deliver health services promptly. The system will soon include all essential medicines for tuberculosis, malaria, reproductive, maternal, and child health. 

Now, stronger collaboration with the private sector is needed to expand innovations, and to prevent further disruptions from COVID-19. The government and its partners should join forces with the private sector to develop or expand innovations, such as the home delivery of medicines or the availability of telemedicine during lockdowns. Collaborations in the health sector that aim to optimize the benefits from technology will further enhance health services, save time, and minimize exposure to infectious diseases.


Getting a COVID-19 vaccine to 7.8 billion global citizens calls for a combination of meaningful partnerships and innovative supply chain technology

The Hill: COVID-19 doesn't care about New York or New Delhi

Marian W. Wentworth and Wade Warren, January 3, 2021

It is both a moral imperative—and in the strategic interest of wealthier countries—to aid in the pursuit of vaccinating 7.8 billion global citizens. Our global health security is only as strong as the weakest link in the chain. Yet even in fully industrialized nations with robust health infrastructure, the logistics of the world’s largest-ever vaccination campaign are daunting. 

Because of how interconnected the world is today, the economic impacts of COVID-19 have been more severe than in past pandemics. Modern economies depend on global travel, global trade and global supply chains. To combat economic instability and severe global health insecurity, we must look to an ideal combination of meaningful partnerships and innovative supply chain technology to deliver COVID-19 vaccines worldwide.

This ideal combination isn’t an entirely new concept. Through decades of work in delivering treatments for malaria and HIV or in making family planning accessible to populations far from industrial centers, we have learned how to hone complex supply chains and work closely with governments, civil society, the private sector and health care workers on locally led solutions. 

From these experiences, we know more about what a 21st century solution to the supply chain looks like. Take, for example, the idea of the Control Tower, which is a set of tools and techniques that enable experts to proactively manage their end-to-end supply chains through increased visibility and predictive insights. Some experts estimate that as much as 20 percent of vaccines are lost due to cold chain issues or irregularities, but a modern, effective Control Tower can monitor temperature irregularities in real time and guide interventions before the product is lost. 


Even as we battle COVID-19, we must increase malaria surveillance and monitoring for signs of new drug-resistant mutations

Scientific American: A New Strain of Drug-Resistant Malaria Has Sprung Up in Africa. Here’s how we fight back

Tom Hall, Senior Technical Advisor for Malaria, January 2, 2021

More than 90 percent of all malaria deaths occur in Africa, and there is a threat that could set progress back again. Researchers in Rwanda have identified a new strain of drug-resistant malaria. We must strengthen surveillance and monitoring for signs of new mutations, even as we battle the COVID-19 pandemic. In addition to basic tactics like increasing people’s access to insecticide-treated mosquito nets, countries can take a few actions to help make a difference, including ensuring that providers and patients use meds effectively; taking action to maximize the longevity of ACTs; developing next-generation treatments; expanding lab testing capacity; and developing a cross-border action plan with neighboring countries. Southeast Asia has already seen this mutation as of 2013 and is holding it at bay with careful use of drugs that work where they are most needed. We can outsmart this. We must bring our collective human ingenuity and determination to ensure that the continent bearing the world’s greatest burden of malaria stays one step ahead of the emerging threat of this dangerous mutant parasite.


Pooling resources could boost the fight against both COVID-19 and Tuberculosis

Global Health NOW: A 2-Front Battle: COVID-19 Must Reinvigorate the Fight Against TB

Dr. Ersin Topcuoglu, Director of the Health Systems for Tuberculosis Project, December 11, 2020

As the COVID-19 scourge intensifies, it may be weakening our battle against tuberculosis—but pooling resources could boost the fight against both diseases, writes Ersin Topcuoglu, director of the Health Systems for Tuberculosis Project at Management Sciences for Health, in an GHN exclusive commentary.  

It wouldn’t be the first time a public health crisis has catalyzed progress: For example, the first global effort to contain infectious disease—the International Sanitary Conferences that began in 1851—sought to address cholera.

World leaders have committed to treating 40 million people for TB by 2022 and to providing preventive treatment for 30 million more.

Meanwhile, the COVID-19 death toll has passed 1.5 million people. The scourge of both diseases demands informed, inclusive, and empowered public health leadership, writes Topcuoglu, laying out several steps to addressing TB and COVID-19 in tandem.


Countries Need Informed Decision-making through Health Technology Assessment to Allocate Resources during the Pandemic

Think Global Health: Who Gets What and Why?

Hector Castro, MSH Technical Director, September 23, 2020

Half of all medical equipment in Bangladesh’s public health facilities—hospital beds, ventilators, nebulizers, refrigerators, and vehicles—goes unused. Meanwhile, in Uganda, ultrasound machines are overused for a small number of patients, while many in need go without...Why such painful gaps and discrepancies? In an opinion piece for Think Global Health—an initiative from the Council on Foreign Relations—MSH’s Global Lead of Infectious Diseases, Health Financing, Technologies, Data, and Impact, Dr. Hector Castro, discusses the need for health technology assessment to set priorities and allocate precious resources. “As we struggle to contain the current pandemic, our health-care needs will only increase. Short of a global windfall, countries must avoid waste and make do with available resources. Even a lower-income country can make impressive gains, helping its people live longer, healthier lives. Applying health technology assessment smartly to inform their own policies can make a little go a long way.”


For Faster Medical Product Access in Low- and Middle-income Countries, Make Long-term Investments in Regulatory Systems

Think Global Health: A Wake-Up Call Both Brutal and Urgent

Tamara Hafner, MSH Principal Technical Advisor, and Javier Guzman, MSH Technical Director, July 27, 2020

“The pandemic is a brutal and urgent wake-up call that low- and middle-income countries need more effective, efficient regulatory systems.” In an opinion piece for Think Global Health—an initiative from the Council on Foreign Relations—Tamara Hafner and Javier Guzman, both of the MSH-led, USAID MTaPS program, discuss the need for long-term investments in pharmaceutical regulatory systems for faster access to medical products. “As we struggle to meet emergency needs during the pandemic, we have a window of opportunity to overhaul the way we handle the regulation of medical products.”


Behavior Change Is Key to Fighting COVID-19 but Getting the Government to Finance Such Activities Is Not Easy

DEVEX: Inequality and Corruption: Why Peru is Losing Its COVID-19 Battle

Edgar Medina Figueroa, MSH-Peru Executive Director, July 1, 2020

Peru mobilized quickly to fight COVID-19, but the country still finds itself with one of the highest death rates in the region. Public health experts, including MSH-Peru Executive Director Edgar Medina Figueroa, explain where and how the pandemic response has fallen short. 


What If An Early Warning of the Next Pandemic Was Not in the Jungle, But in Your Living Room? 

The Hill: Can Veterinarians Save Us from the Next Pandemic?

Ashley Arabasadi, MSH Senior External Affairs Officer, May 29, 2020

Three-quarters of all emerging diseases are zoonotic, and a pandemic threat anywhere is a threat everywhere. In an opinion article for The Hill, MSH’s Senior External Affairs Officer, Ashley Arabasadi, and Dr. Tracey McNamara, a veterinary pathologist and “discoverer” of the West Nile Virus discuss the need to invest in animal disease surveillance to prevent the next pandemic.

How Tiny Madagascar’s Experience Stopping an Outbreak of the Plague in 2017 Can Provide Other Countries with Valuable Lessons on Contact Tracing

Voice of America: How Contact Tracers Could Help Control COVID-19

John Yanulis, Madagascar Project Director, May 15, 2020

As countries look to contact tracing to break the chains of transmission of COVID-19, in an interview with Voice of America, Madagascar Project Director John Yanulis discusses how MSH supported the country's efforts to stem a major outbreak of the plague in 2017 by working with community health volunteers to perform contact tracing, prophylactic treatment administration, and testing referrals. "They're the eyes and ears of the health system," explains Yanulis.

Free Webinar Training For Health Care Workers in the Philippines Helps Prevent Health Workers From Getting Infected and Reduces Further Spread of COVID-19

ABS-CBN News Channel (ANC):  TV interview with Dr. Hasibul Haque, Country Program Director, USAID’s Medicines Technologies and Pharmaceutical Services (MTaPS) project

In a live interview on ABS-CBN News Channel (ANC), May 12, 2020, Country Program Director Dr. Hasibul Haque of USAID’s Medicines Technologies and Pharmaceutical Services (MTaPS) project, led by MSH, answers questions about MTaPS training courses, their target, reach, key messages, and effectiveness, as well as perspectives and challenges of the health care workers around COVID-19 infection prevention and personal protective equipment.

What Specific Actions the Nigeria Government Can Take to Strengthen Its Health Infrastructure to Fight Pandemics Like COVID-19, Blueprint

Blueprint: COVID-19 Has Exposed Lapses in Nigeria’s Health Sector

Dr. Kingsley Ochei, MSH Infectious Disease Specialist, May 7, 2020

Nigeria is currently dealing with its largest Lassa fever outbreak, while at the same time addressing COVID-19. In an interview, Dr. Kingsley Ochei, a lab and infectious disease specialist at MSH, discusses what Nigeria must do to improve its health system to fight priority diseases such as Lassa fever, HIV, COVID-19, and malaria. Over the years, little attention has been paid to the health sector and the decay in the public health facilities. “The COVID-19 pandemic exposes this lapse for the government to address,” says Ochei. “Yet, the pandemic has also shown that we have capable medical personnel… who can rise to the occasion any day to address the issues around health security.”

COVID-19 Vaccine: Does the Benefit Outweigh the Risk for Participants?, Medical Ethics Advisor

Medical Ethics Advisor: The COVID-19 Vaccine: Usual Ethical Questions in Unusual Times

Marian W. Wentworth, MSH President and CEO, May 1, 2020

Marian W. Wentworth, MSH President and CEO, discusses the ethical implications of fast-tracking human trials for a COVID-19 vaccine. The underlying ethical principles are the same as with vaccine development in general. “What’s changing now is external circumstances and the lack of normative data to answer ethical questions,” Wentworth notes.

No, Vaccines Are Not Cash Cows for the Pharmaceutical Industry, The Washington Post

The Washington Post: Five Myths about Vaccines

Marian W. Wentworth, MSH President and CEO, May 1, 2020

As a long-time observer of vaccine development, Marian W. Wentworth’s recent interview in The Guardian is quoted in a commentary on a vaccine against novel coronavirus.


A Picture Is Emerging of the Kind Of Society Needed to Withstand the Future Outbreaks Scientists Say Are Inevitable, The Guardian

The Guardian: 10 Key Lessons for the Future to Be Learned from Fighting Covid-19

Ashley Arabasadi, MSH Health Security Policy Advisor, May 1, 2020

Months into this epidemic, even basic information about the coronavirus is still unclear. How infectious is it? How deadly? Yet the basic principles for containing a disease, developed and refined with reference to hundreds of previous epidemics, have held true for COVID-19.


Global Health Programs: Detecting Disease Outbreaks Locally And Preventing Them from Spreading Globally, The Hill

The Hill: Investments in Global Health Programs Pay Off in Pandemic Response

Marian W. Wentworth, MSH President and CEO, April 19, 2020

Global health programs, mainly implemented by international NGOs, have been working on pandemic preparedness and prevention behind the scenes for years. The current crisis demands that we dig deep to fund our current response, both domestic and internationally. While the current scenario is novel to many of us, NGOs are a reliable tool at many governments’ disposal and one upon which many lives depend.


The Greatest Challenge Is What Comes after We Have a COVID-19 Vaccine: Navigating the Broad Spectrum of Sociopolitical and Economic Barriers to Immunization, Truthout

Truthout: A COVID-19 Vaccine Will Not Be Enough — We Need a Plan to Distribute It

Marian W. Wentworth, MSH President and CEO, April 16, 2020

Distrust and spread of misinformation around vaccines, and a possible short supply, unable to meet the demands of the population, are some of the issues that have long haunted global immunization efforts and will need to be taken into consideration once (or if) a COVID-19 vaccine comes to market. According to MSH President and CEO, Marian W. Wentworth, the “first-come, first served” model will likely be the case for a COVID-19 vaccine. “No matter how fast we scale up,” says Wentworth, “it’s going to be true on day one, the total number of doses available is less than the need.” 



Breaking the Cycle of Panic and Ensuring Countries Have the Resources to Stop Outbreaks at the Source, in a Recent Canadian Radio Interview

Jerry Agar Show: Predicting the Pandemic 

Ashley Arabasadi, MSH Health Security Policy Advisor, April 14, 2020

"We have an opportunity now to really look ahead and put these pandemic preparedness plans in place, to make effective strengthen health systems, not only internally [in the US] but globally, that can help make everybody safer," says MSH Health Security Policy Advisor Ashley Arabasadi in an interview with Canadian radio host, Jerry Agar, about breaking the cycle of panic and neglect countries face when it comes to health emergencies and the need ensure that governments in low- and middle-income countries have the resources and capacity to handle outbreaks and stop them more quickly at the source. "This is what we [at MSH] do and this is where the best investment in funds can go - is strengthening the health system."



While the Official 12- To 18-month Timeframe Still Stands, Experimental COVID-19 Inoculations for High-risk Groups Could Be Rolled Out Much Earlier, The Guardian

The Guardian: Coronavirus Vaccine: When Will We Have One?

Marian W. Wentworth, MSH President and CEO, April 12, 2020

The COVID-19 pandemic is forcing change at almost every step in the vaccine development process. What kind of timeline for an effective vaccine can we hope to expect? MSH President and CEO, Marian W. Wentworth, a long-time observer of vaccine development, shares her insight with The Guardian.



Pathogens See No Borders: The Importance of Evidence-based Information and Meaningful Investments in Preparedness, 45 North

">45 North: Interview with Ashley Arabasadi: Journalists play an important role in sharing reliable information from public health experts

Ashley Arabasadi, MSH Health Security Policy Advisor, April 9, 2020

Romania's 45 North, a nonprofit news organization, interviewed MSH Health Security Policy Advisor, Ashley Arabasadi, about the role journalists and NGOs play in preventing and/or fighting epidemics, the use of surveillance as a tool for controlling and preventing disease, and why"investing in preparedness makes financial sense too, as experts have known that the cost of prevention is a fraction of what an epidemic can cost to the global economy."  



Health Security Experts Are Always Thinking about Preventing the Worst Case Scenario – A Pandemic. When It Happens, It’s Almost Like You Are Watching in Slow Motion, The Irish Times 

The Irish Times: Coronavirus: ‘you may have heard of a game called Plague Inc’

Ashley Arabasadi, MSH Health Security Policy Advisor, March 29, 2020

In a Q&A with The Irish Times, MSH’s Ashley Arabasadi, shares her perspective working in health security during a global pandemic: “Seeing that [pandemic] simulation actually play out in real life has been terrifying, but really interesting in terms of the amount of preparedness we have, versus what we need in reality.”


The Link Between the World’s Top Infectious Killer and Covid-19’s Lethal Invasion, Global Health NOW

Global Health NOW: We Need to Move Faster to Introduce New TB Drugs

Andre Zagorski, MSH Senior Principal Technical Advisor, March 24, 2020

MSH’s Andre Zagorski, on the fight against TB, the world’s top infectious killer, in an Op-ed for Global Health NOW: “The COVID-19 response can draw on challenges and lessons from TB programs that emphasize investments in research and rapid uptake of new diagnostic, prevention, and treatment tools for universal health coverage.”